Actualités de BRUSSELS
- Langue:
- Médias:
- Période:
- Période:Totale
- plus
Tennis Champion Caroline Wozniacki and UCB Launch Advantage Hers Campaign for Women with Chronic Inflammatory Diseases
Brussels, Belgium (ots/PRNewswire) - - Grand Slam winner Caroline Wozniacki is the highest-ranking female athlete known to have been diagnosed with rheumatoid arthritis whilst still playing professional tennis - Advantage Hers will equip and empower women around the world living with chronic inflammatory diseases, ...
plusFinal Phase II Results for UCB's Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) Published in Blood Advances
Brussels (ots/PRNewswire) - - Phase II data demonstrated clinically meaningful platelet count increases with meaningful decreases in IgG concentration - Rozanolixizumab's subcutaneous route of administration shows potential to deliver targeted individualized patient care for people living with Primary Immune ...
plusUCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer's Disease
Brussels (ots/PRNewswire) - - UCB to provide to Roche and Genentech exclusive, world-wide license to UCB's UCB0107, an innovative anti-Tau antibody treatment - UCB will receive an initial upfront payment and, after positive completion of proof-of-concept in Alzheimer's Disease, is eligible to receive further ...
plusUCB Half Year Report 2020
Brussels (ots/PRNewswire) - - UCB's resilient product portfolio drives continued company growth - Revenue increased to EUR 2.6 billion and net sales to EUR 2.5 billion, both +12%, +9% CER or +10% at CER and adjusted for divestitures respectively - Underlying profitability (adj. EBITDA) was EUR 783 million (+8%, 0% CER) or a ratio of 30% - Ra Pharma acquisition closed early April, Engage Therapeutics acquired in June, co-promotion agreement for Cimzia® with Ferring in July - ...
plusEuroclear Holding, Euroclear Investments, Euroclear SA/NV
Euroclear: Directorate Changes
Brussels (ots/PRNewswire) - The Euroclear group announces that Marc Antoine Autheman has decided to step down as the Chairman and Director of the Euroclear boards. During Mr Autheman's eight year tenure, Euroclear's strategy has resulted in its strong financial position and performance, delivering consistently growing returns for shareholders and value for its financial market participants, whilst adapting to meet the requirements of the post-financial crisis regulatory and ...
plusUCB Acquires Engage Therapeutics: Staccato® Alprazolam - A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy
Brussels, Belgium (ots/PRNewswire) - - Underlines UCB's leadership in epilepsy by adding Staccato® Alprazolam, a drug-device-combination with the potential to be the first on-demand, single-use treatment to rapidly terminate an active epileptic seizure - Staccato® Alprazolam could be a potential solution for ...
plusAnywhere365, the Leading Microsoft Teams Focused Cloud Contact Center Provider, Receives a Follow-on Investment of EUR20 Million From Existing Investor Bregal Milestone
Rotterdam, Netherlands, London, Atlanta and Brussels (ots/PRNewswire) - Appoints Senior Microsoft Executive Will Blench to the Board of Directors and Hires Nasdaq-Experienced Finance Director Frans Koch as CFO to Accelerate Global Expansion Anywhere365, the leading software provider for Enterprise Dialogue ...
plusEuroclear Business and Financial Update - Q1 2020
Brussels (ots/PRNewswire) - - Business Income rose 15% to EUR 321 million - Banking and Other Income decreased 14% to EUR 62 million - Q1 20 revenues up 9% year-on-year, to EUR 383 million - Operating costs up by 4% to EUR 213 million, in line with expectations - Net profit was up 29% to EUR 127 million - Dividend approval to be postponed to Q4 2020 in light of recent ECB guidance - Liquidity initiative stopped due to ...
plusUCB's General Meeting of Shareholders
Brussels (ots/PRNewswire) - - Update on attendance and voting instructions relating to UCB's General Meeting of 30 April 2020 - Implementation of Royal Decree n°4 of 9 April 2020 on various provisions regarding the legislation on co-ownership and companies and associations, in the framework of the fight against the Covid-19 pandemic - No physical presence at General Meeting allowed and votes can only be submitted by ...
plusUCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients
Brussels (ots/PRNewswire) - - The transaction, which was announced October 10, 2019, will enhance UCB's potential to be a leader in myasthenia gravis by adding zilucoplan , a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside rozanolixizumab , UCB's FcRn targeting ...
plusEmakina Group Results 2019: More Sustained Growth in Activities in the Second Half of the Year and Operating Performance Under Control
Brussels (ots/PRNewswire) - Inside & Regulated information - Summary of the https://www.emakina.group/en-US/InvestorRelations/RegulatedNews http://www.emakina.group/ (Euronext GROWTH Bruxelles : ALEMK), leading international group of independent agencies, announces its 2019 annual results. Consolidated sales ...
plusWorld Financial Association Calls for Extraordinary Measures From Central Bank Governors and Head of States: Close Financial Markets and Trading Platforms for Two Weeks
Brussels (ots/PRNewswire) - In an unprecedented move, the World Financial Association has issued a call today for a general shut-down of the financial markets and trading platforms for a period of two weeks. According to the WFA, this comes because while authorities throughout the world have asked all main economies ...
plusUCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting
Brussels (ots/PRNewswire) - - Phase II data demonstrate that rozanolixizumab was well tolerated by patients with primary ITP across all dose groups - Clinically relevant improvements in platelet count and decrease in immunoglobin G (IgG) levels were observed in all dose groups - Safety, tolerability and efficacy ...
plusUCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases
- Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB's rozanolixizumab, an FcRn targeting antibody also in phase 3 - Will enrich UCB's pipeline; zilucoplan is a novel, ...
plusEmakina Group Half-year Results: Sales Up, and Impact of Resource Occupation Rate on Margins
Inside and Regulated information - condensed translation of the official Official French version (https://www.emakina.group/en-US/News/Press/fr_FR) Brussels (ots/PRNewswire) - - H1 consolidated revenues +1.4% EUR 47,425,059 compared with EUR 46,763,193 for 2018 (identical at constant scope) - H1 EBITDA -27.0% EUR 2,750,789 compared with EUR 3,767,360 for 2018 (% of ...
plusExperts Consider Osteoporosis to Be a Silent Epidemic Which Is Neglected and Under Addressed, According to New Survey Released Today
- Osteoporosis is estimated to affect 200 million people worldwide1 and results in a fracture every 3 seconds2 yet a new survey reveals bone specialists in Europe think its impact is not fully recognised3 - Specialists (82%) believe osteoporosis is a silent epidemic, yet only 24% believe their healthcare system is ...
plusMartini Racing Ciclismo: Tom Boonen Appointed as Road Captain
Brussels (ots/PRNewswire) - Tom Boonen is back in the peloton, albeit a so-called "horecapeloton." Martini Racing Ciclismo will be made up of participants from the HOtel, REstaurant and CAtering sector. Former world champion, three times winner of the Ronde Van Vlaanderen and four times winner of the Paris-Roubaix classic, Boonen has now taken on the role of Road Captain in support of a project aiming to get workers in ...
plusEIT Digital: Enhancing the Global Impact of European Innovation
Brussels (ots/PRNewswire) - The EIT Digital Strategic Innovation Agenda 2020-2022 EIT Digital presented its Strategic Innovation Agenda for the period 2020-2022, outlining plans to strengthen Europe's position in the digital world and to help business and entrepreneurs to be at the forefront of digital innovation. The document was officially handed over to European Commission Vice-President Andrus Ansip and MEP Eva Kaili. ...
plusGoodyear Pushes the Limit With New Race-inspired Eagle F1 SuperSport Range for Road and Track
Brussels (ots/PRNewswire) - - Three-tier range comprising SuperSport, SuperSport R and SuperSport RS - Innovative technologies enable significant improvements to braking distances and lap times - Caters to growing Ultra Ultra High Performance (UUHP) segment, with 39 SKUs arriving between February and November 2019 with possible fitments from Volkswagen Golf GTI to ...
plusGoodyear's Ultimate All-rounder: New Eagle F1 Asymmetric 5 Combines Luxurious Comfort With Superior Wet Braking and Dry Handling Performance
Brussels (ots/PRNewswire) - - Successor to popular and acclaimed Eagle F1 Asymmetric 3 range - Innovative technologies unlock significant improvements in wet braking and dry handling without compromising ride comfort or road noise - Caters to growing Ultra High Performance (UHP) market, with 61 SKUs arriving between ...
plusThe European Travel Commission
European Travel Commission Reports Sustained Expansion in Europe Over the Summer Months
Brussels (ots/PRNewswire) - European destinations reported healthy growth this summer despite rising political risks and less relaxed financial conditions posing a threat to the global economic outlook. Growth momentum was boosted by robust intra-European demand and improved air connectivity, notably from China. According to the European Travel Commission's latest ...
plusUCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis Into Confirmatory Development Phase
Brussels (ots/PRNewswire) - - Positive outcomes in proof-of-concept study with subcutaneous rozanolixizumab in patients with myasthenia gravis (MG): clinically meaningful improvement in multiple disease-related endpoints - Strong 68% mean reduction of Serum IgG and IgG Autoantibodies observed - Safety profile ...
plusGoodyear Eagle F1 Asymmetric 3 SUV Fitted on Audi e-tron in San Francisco
Brussels (ots/PRNewswire) - Goodyear ultra-high performing tires are chosen for Audi's first ever electric SUV Audi revealed its e-tron today, which is the first fully electric SUV to be commercialized by the German car manufacturer. Goodyear has supplied this groundbreaking model with its Eagle F1 Asymmetric 3 SUV tires in 265/45R21 SUV size. (Photo: ...
plusEIT Digital at the Heart of Europe's Digital Innovation Priorities
Brussels (ots/PRNewswire) - With activities focused on Digital Infrastructure (data science, machine learning, cybersecurity and next generation networks), Digital Industry, Digital Wellbeing, Digital Cities and Digital Finance, the results and impact of EIT Digital are at the heart of the priorities, recently identified by the European Commission and national ...
plusUCB Announces Approval of NEUPRO® in China to Treat Parkinson's Disease
Brussels (ots/PRNewswire) - - NEUPRO now approved in China for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's Disease as monotherapy (i.e. without levodopa) or in combination with levodopa - NEUPRO approval in China reinforces UCB's ongoing commitment to supporting patient value across China and to offering Chinese patients additional ...
plusNew UCB Data Presented at the Annual European Congress of Rheumatology (EULAR 2018) Serves Key Patient Populations Including Ankylosing Spondylitis, Psoriatic Arthritis, and Women with Chronic Inflammatory Diseases
Brussels (ots/PRNewswire) - - Late-breaking oral presentation on bimekizumab shows significant potential for treating ankylosing spondylitis (AS) - Oral presentation on CIMZIA® (certolizumab pegol) pregnancy outcomes shows no increased risk of major congenital malformations compared to the general population nor an ...
plusUCB Joins with ILAE and IBE to Encourage World Health Assembly Members to Continue Recognition of Epilepsy as Global Health Priority
Brussels and Geneva (ots/PRNewswire) - - Significant gaps in epilepsy management, awareness, and effective treatment access continue around the world - Groups are launching a call to action for public and private engagement to join the fight against Epilepsy through a sustained commitment towards the Resolution on ...
plusUCB Announces BRIVIACT® (Brivaracetam) now Approved by FDA to Treat Partial-onset (Focal) Seizures in Pediatric Epilepsy Patients
Atlanta and Brussels (ots/PRNewswire) - - BRIVIACT® (brivaracetam) CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with partial-onset seizures - Approval provides pediatric epilepsy patients a treatment option which can be initiated at a therapeutic ...
plusUCB Announces Positive CHMP Opinion for CIMZIA® (certolizumab pegol) in Patients with Moderate-to-Severe Plaque Psoriasis
Brussels (ots/PRNewswire) - Strictly not for UK/Irish media - CIMZIA® (certolizumab pegol) Phase 3 psoriasis data demonstrated significant and clinically meaningful improvements in biologic-naïve and previously treated patients, with clinical benefit maintained up to one year[1] - This milestone represents UCB's ...
plus